Damora Therapeutics, Inc.
NNASDAQ:GLTOShare Statistics
As of December 31, 2025, Damora Therapeutics, Inc. has 1.60M shares outstanding.
| Shares Outstanding | 1.60M |
Valuation Ratios
These figures are as of December 31, 2025.
| PB Ratio | -0.06 |
| P/TBV Ratio | -0.17 |
| P/FCF Ratio | -4.53 |
| P/OCF Ratio | -4.53 |
Financial Position
As of December 31, 2025, Damora Therapeutics, Inc. maintains a current ratio of 12.98, meaning it holds 13.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.98 |
| Quick Ratio | 12.88 |
| Debt / Equity | 0.03 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -151.15, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -151.15 |
Dividends & Yields
These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -22.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.
| FCF Yield | -22.08 |
Stock Splits
Damora Therapeutics, Inc.'s most recent stock split took place on August 30, 2024 with a 25:1 split ratio.
| Last Split Date | 8/30/2024 |
| Split Ratio | 25:1 |
Scores
As of December 31, 2025, Damora Therapeutics, Inc. has an Altman Z-Score of -3.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.28 |